BR0010648A - Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril - Google Patents

Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril

Info

Publication number
BR0010648A
BR0010648A BR0010648-8A BR0010648A BR0010648A BR 0010648 A BR0010648 A BR 0010648A BR 0010648 A BR0010648 A BR 0010648A BR 0010648 A BR0010648 A BR 0010648A
Authority
BR
Brazil
Prior art keywords
biodegradable microspheres
microspheres
release
radiosensitizing
preparing
Prior art date
Application number
BR0010648-8A
Other languages
English (en)
Inventor
Nathalie Faisant
Jean-Pierre Benoit
Philippe Menei
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of BR0010648A publication Critical patent/BR0010648A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE MICROESFERAS BIODEGRADáVEIS QUE LIBERAM UM AGENTE ANTICANCEROSO RADIOSSENSIBILIZADOR, PROCESSO DE PREPARAçãO DE MICROESFERAS BIODEGRADáVEIS, E, SUSPENSãO CONSTITUìDA DE UMA SOLUçãO ESTéRIL". A presente invenção tem por objeto a utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador para a fabricação de um medicamento destinado a ser utilizado de maneira simultânea, separada ou distribuída ao longo do tempo, com uma radioterapia, para o tratamento do glioblastoma. A utilização das microesferas biodegradáveis de acordo com a invenção permite atingir uma duração de sobrevida dos pacientes de pelo menos 90 semanas, mantendo, ao longo do tempo, uma concentração terapeuticamente eficaz no espaço parenquimatoso. As microesferas utilizadas contêm, de preferência, 5-fluoroacila revestida com poli(d,1-ácido láctico-co-ácido glicólico). As microesferas são implantadas por injeção intratissular, após exérese do tumor, nas paredes do foco operatório. A radioterapia focalizada no volume tumoral é dosada a 60 Gy ao longo de aproximadamente seis semanas. A presente invenção refere-se também a um processo de preparação das microesferas biodegtadáveis por emulsão-extração, bem como a uma suspensão contendo microesferas biodegradáveis eventualmente obtidas por meio deste processo.
BR0010648-8A 1999-05-17 2000-05-17 Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril BR0010648A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906207A FR2793684B1 (fr) 1999-05-17 1999-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
PCT/FR2000/001315 WO2000069413A1 (fr) 1999-05-17 2000-05-17 Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome

Publications (1)

Publication Number Publication Date
BR0010648A true BR0010648A (pt) 2002-02-19

Family

ID=9545636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010648-8A BR0010648A (pt) 1999-05-17 2000-05-17 Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril

Country Status (30)

Country Link
US (2) US6803052B2 (pt)
EP (2) EP1053746B1 (pt)
JP (1) JP5230045B2 (pt)
KR (1) KR100649948B1 (pt)
CN (1) CN1210020C (pt)
AR (1) AR024008A1 (pt)
AT (1) ATE228353T1 (pt)
AU (1) AU775320B2 (pt)
BG (1) BG64936B1 (pt)
BR (1) BR0010648A (pt)
CA (1) CA2388656C (pt)
CZ (1) CZ20014137A3 (pt)
DE (1) DE60000842T2 (pt)
DK (1) DK1053746T3 (pt)
EA (1) EA004943B1 (pt)
ES (1) ES2185544T3 (pt)
FR (1) FR2793684B1 (pt)
HK (1) HK1047044B (pt)
HU (1) HUP0201224A3 (pt)
IL (2) IL146467A0 (pt)
MX (1) MXPA01011919A (pt)
NO (1) NO331686B1 (pt)
NZ (1) NZ515515A (pt)
PL (1) PL201614B1 (pt)
PT (1) PT1053746E (pt)
SI (1) SI1053746T1 (pt)
SK (1) SK16342001A3 (pt)
TW (1) TWI229608B (pt)
WO (1) WO2000069413A1 (pt)
ZA (1) ZA200109415B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010489A2 (de) 1999-08-05 2001-02-15 MAP Medizintechnik für Arzt und Patient GmbH & Co. KG Vorrichtung zur zufuhr eines atemgases, befeuchtungsvorrichtung, atemgasschlauch und anschlussvorrichtung hierfür
AUPR098300A0 (en) 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
ES2385030T3 (es) 2001-06-29 2012-07-17 Medgraft Microtech, Inc. Implantes inyectables biodegradables y procedimientos relacionados con su fabricación y uso
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US8986737B2 (en) 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
CN108837255B (zh) 2003-06-20 2020-12-22 瑞思迈私人有限公司 带有加湿器的可吸入气体设备
WO2005023293A1 (en) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
EP1732594A4 (en) * 2004-03-18 2007-10-17 St Lukes Hospital METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE
US8088413B2 (en) * 2004-04-16 2012-01-03 Nuvue Therapeutics, Inc. Methods for improved cryo-chemotherapy tissue ablation
WO2005099367A2 (en) * 2004-04-16 2005-10-27 Critical Care Innovations, Inc. Systems and methods for improving image-guided tissue ablation
ES2361919T3 (es) 2004-09-07 2011-06-24 Biocompatibles Uk Limited Suministro de fármaco a partir de agentes embólicos.
US8702580B2 (en) * 2004-10-06 2014-04-22 Brainlab Ag Method and device for assisting in a tissue treatment
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
CN1299685C (zh) * 2005-01-26 2007-02-14 上海大学 氟尿嘧啶载药微球及其制备方法
CN100340297C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 抗癌体内植入剂
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂
CN100464785C (zh) * 2005-08-30 2009-03-04 孔庆忠 一种抗癌药物缓释注射剂及其应用
CN1923282B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN100500214C (zh) * 2006-01-09 2009-06-17 济南帅华医药科技有限公司 抗癌药物缓释注射剂
CN100563711C (zh) * 2006-01-18 2009-12-02 济南帅华医药科技有限公司 一种抗癌缓释注射剂
CN100531717C (zh) * 2006-01-23 2009-08-26 济南帅华医药科技有限公司 含氨甲喋呤增效剂的抗癌缓释剂
CN100500215C (zh) * 2006-01-23 2009-06-17 济南帅华医药科技有限公司 含氨甲喋呤及其增效剂的缓释注射剂
CN100531715C (zh) * 2006-01-23 2009-08-26 济南帅华医药科技有限公司 氨甲喋呤缓释注射剂
CN1923173B (zh) * 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
CN100486560C (zh) * 2006-03-06 2009-05-13 济南康泉医药科技有限公司 一种含血管抑制剂的复方抗癌缓释注射剂
WO2007105218A2 (en) * 2006-03-14 2007-09-20 Yeda Research And Development Co. Ltd. Composition and method for brain tumor therapy
CN100464736C (zh) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
CN109125286A (zh) 2011-12-13 2019-01-04 安吉尼科分子传输公司 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞
US10342769B2 (en) * 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
MX2022006824A (es) 2019-12-05 2022-09-19 Univ West Virginia Nanoesferas de plga cargadas con proteinas.
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
WO1998016242A1 (en) * 1996-10-16 1998-04-23 Regeneron Pharmaceuticals, Inc. Method of enhancing the delivery of growth factors
WO1998043977A1 (en) * 1997-03-31 1998-10-08 Toray Industries, Inc. Quinolinomorphinane derivatives and medicinal use thereof
EP1028735A4 (en) * 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN

Also Published As

Publication number Publication date
HUP0201224A3 (en) 2004-05-28
EP1228755A1 (fr) 2002-08-07
CA2388656C (fr) 2011-04-26
HK1047044A1 (en) 2003-02-07
DE60000842T2 (de) 2003-08-28
NO20015501D0 (no) 2001-11-09
DK1053746T3 (da) 2003-03-31
BG106106A (en) 2002-05-31
NO331686B1 (no) 2012-02-20
FR2793684B1 (fr) 2001-08-10
CZ20014137A3 (cs) 2002-06-12
AR024008A1 (es) 2002-09-04
HUP0201224A2 (hu) 2002-11-28
US20030175356A1 (en) 2003-09-18
AU4764100A (en) 2000-12-05
PL201614B1 (pl) 2009-04-30
EA200101206A1 (ru) 2002-04-25
FR2793684A1 (fr) 2000-11-24
CN1210020C (zh) 2005-07-13
SK16342001A3 (sk) 2002-08-06
TWI229608B (en) 2005-03-21
SI1053746T1 (en) 2003-04-30
EA004943B1 (ru) 2004-10-28
JP5230045B2 (ja) 2013-07-10
KR20020000178A (ko) 2002-01-04
EP1053746A1 (fr) 2000-11-22
DE60000842D1 (de) 2003-01-09
PL352372A1 (en) 2003-08-25
WO2000069413A1 (fr) 2000-11-23
KR100649948B1 (ko) 2006-11-24
NZ515515A (en) 2004-02-27
PT1053746E (pt) 2003-04-30
ZA200109415B (en) 2003-01-29
US20020051749A1 (en) 2002-05-02
CA2388656A1 (fr) 2000-11-23
MXPA01011919A (es) 2002-05-06
IL146467A0 (en) 2002-07-25
US7041241B2 (en) 2006-05-09
AU775320B2 (en) 2004-07-29
US6803052B2 (en) 2004-10-12
ES2185544T3 (es) 2003-05-01
NO20015501L (no) 2002-01-09
EP1053746B1 (fr) 2002-11-27
JP2002544219A (ja) 2002-12-24
CN1356892A (zh) 2002-07-03
BG64936B1 (bg) 2006-10-31
HK1047044B (zh) 2005-12-23
ATE228353T1 (de) 2002-12-15
IL146467A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
Gao et al. Chlorella‐loaded antibacterial microneedles for microacupuncture oxygen therapy of diabetic bacterial infected wounds
EA200101206A1 (ru) Применение биоразлагаемых микросфер, высвобождающих противораковый агент, для лечения глиобластомы
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
Wang et al. Inflammatory microenvironment‐responsive nanomotors with NIR photothermal effect for deep inflammation elimination and infection inhibition
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
BR0012488A (pt) Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica
EP0563278A4 (pt)
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
BR9910251A (pt) Estimulação hematopoiética
DK0777739T3 (da) Genterapeutisk behandling af karsygdomme med et cellespecifikt cellecyklusafhængigt aktivt stof
ES8400241A1 (es) Procedimiento para la obtencion de medios antimicoticos con mayor liberacion de sustancia activa.
BR9802542A (pt) Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios.
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
JP2022169627A (ja) 腋臭を治療する方法
Jia et al. Microneedles loaded with glutathione‐scavenging composites for nitric oxide enhanced photodynamic therapy of melanoma
BR0210994A (pt) Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células
Xiong et al. Immune‐Vascular Synergy: A Photodynamic Hydrogel Activating ALDH2 to Combat Inflammation and Enhance Angiogenesis in Diabetic Wound Healing
Sun et al. Sustained release of IGF-1 by 3D mesoporous scaffolds promoting cardiac stem cell migration and proliferation
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
Xian et al. Engineering Mesenchymal Stem Cells with Antioxidant Catalase‐Loaded Metal–Organic Frameworks for Targeted Spinal Cord Injury Therapy
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
BR0110150A (pt) Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
RU95120165A (ru) Лекарственный препарат иммунозамещающего действия на основе клеточной суспензии и способ лечения синдрома приобретенного иммунодефицита (вич-инфекции) с использованием этого препарата

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/16, A61K 31/495, A61P 35/00

Ipc: A61K 9/16 (2009.01), A61P 35/00 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.